Image of Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

LITERATURE

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study


An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its caused
coronavirus disease 2019 (COVID-19) have been reported in China since December 2019. More than
16% of patients developed acute respiratory distress syndrome, and the fatality ratio was about 1%–2%.
No specific treatment has been reported. Herein, we examined the effects of Favipiravir (FPV) versus
Lopinavir (LPV)/ritonavir (RTV) for the treatment of COVID-19.


Availability

Avigan-001Titan CenterAvailable

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
Engineering xxx (xxxx) xxx
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous